Alvotech (ALVO) Cash from Financing Activities (2023 - 2026)
Alvotech (ALVO) posted Cash from Financing Activities of -$967000.0 for Q1 2026, down 100.36% on a QoQ basis from $270.8 million in Q4 2025, and up 83.44% year-over-year from -$527150.9 in Q1 2025.
Alvotech (ALVO) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Alvotech's Cash from Financing Activities history runs 4 years deep, the most recent figure standing at -$967000.0 for Q1 2026.
- Quarterly Cash from Financing Activities rose 83.44% year-over-year to -$967000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $275.7 million (up 74.18% YoY) and the FY2025 annual result came in at $270.8 million, down 8.9% from the prior year.
- Cash from Financing Activities was -$967000.0 for Q1 2026 at Alvotech, down from $270.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $297.0 million in Q4 2024 and bottomed at -$136.9 million in Q3 2024.
- A 4-year average of $61.0 million and a median of $12.3 million in 2023 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 1977.64% in 2025, while the deepest fall reached 104.38% in 2025.
- Alvotech's Cash from Financing Activities stood at $20.7 million in 2023, then surged by 1337.55% to $297.0 million in 2024, then dropped by 8.84% to $270.8 million in 2025, then sank by 100.36% to -$967000.0 in 2026.
- Business Quant data shows ALVO's Cash from Financing Activities at -$967000.0 in Q1 2026, $270.8 million in Q4 2025, and -$77.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Alvotech | 935.87 Mn | 935.87 Mn | 5.09 Mn | -967,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -967,000.00 |
| Mar 31, 2026 | -967,000.00 |
| Dec 31, 2025 | 270.77 Mn |
| Dec 31, 2025 | 270.77 Mn |
| Sep 30, 2025 | -77.24 Mn |
| Sep 30, 2025 | -77.24 Mn |
| Jun 30, 2025 | 83.15 Mn |
| Jun 30, 2025 | 83.15 Mn |
| Mar 31, 2025 | -5.84 Mn |
| Mar 31, 2025 | -5.84 Mn |
| Dec 31, 2024 | 297.01 Mn |
| Dec 31, 2024 | 297.01 Mn |
| Sep 30, 2024 | -136.89 Mn |
| Sep 30, 2024 | -136.89 Mn |
| Jun 30, 2024 | 4.00 Mn |
| Jun 30, 2024 | 4.00 Mn |
| Mar 31, 2024 | 133.18 Mn |
| Mar 31, 2024 | 133.18 Mn |
| Dec 31, 2023 | 20.66 Mn |
| Dec 31, 2023 | 20.66 Mn |